Form DEFA14A Bionano Genomics, Inc.
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
|
☐
|
Preliminary Proxy Statement
|
|||||
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|||||
|
☐
|
Definitive Proxy Statement
|
|||||
|
☒
|
Definitive Additional Materials
|
|||||
|
☐
|
Soliciting Material under §240.14a-12
|
|||||
|
|
||||||
|
Bionano Genomics, Inc.
|
||||||
|
(Name of Registrant as Specified In Its Charter)
|
||||||
|
|
||||||
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
||||||
Payment of Filing Fee (Check all boxes that apply):
|
☒
|
No fee required
|
||
|
☐
|
Fee paid previously with preliminary materials
|
||
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
- AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
- Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
